Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for HYDROXYUREA
- Realizing Effectiveness Across Continents With Hydroxyurea
- Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients
- Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
- Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
- Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
- Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
- Alternative Dosing And Prevention of Transfusions (ADAPT)
- Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
- A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
- Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
- Hydroxyurea and EPO in Sickle Cell Disease
- Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria in the Community
- Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
- Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
- Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
- A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058
- A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
- Clinical Experience of Thalidomide in Thalassemic Patients
- Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia
- Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
- A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
- Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
- Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor
- Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
- Frontline Oral Arsenic Trioxide for APL
- An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
- Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
- Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
- The BENeFiTS Trial in Beta Thalassemia Intermedia
- Reduced Intensity Transplantation for Severe Sickle Cell Disease
- Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS
- Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
- Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
- Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)
- GPS Compared With BAT in AML CR2/CR2p
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera
- Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell Disease
- Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)
- Frontline Asciminib Combination in Chronic Phase CML
- Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
- Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
- Hydroxyurea Optimization Through Precision Study
- Pharmacokinetics of Oral Hydroxyurea Solution
- Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
- T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
- Hydroxyurea and Transfusion
- Management of Severe Acute Malnutrition in SCD, in Northern Nigeria
- Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
- Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients
- Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
- Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
- Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
- Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
- Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
- Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
- A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD
- KISS Study: Kinase Inhibition With Sprycel Start up
- The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
- Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas
- Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
- Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
- Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disea
- The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
- Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
- Mobile-Directly Observed Therapy on Adherence to Hydroxyurea
- A Study of Pevonedistat in Adult East Asian Participants
- HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
- SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia
- Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
- Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
- The Role of Endothelin-1 in Sickle Cell Disease
- Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
- Macitentan in Pulmonary Hypertension of Sickle Cell Disease
- Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)
- Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
- The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
- Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II
- EXTEND EXpanding Treatment for Existing Neurological Disease
- Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
- A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
- Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
- European Sickle Cell Disease Cohort - Hydroxyurea
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
- Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)
- Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
- Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
- Treatment of Hemoglobin SC Disease With Hydroxyurea
- Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
- Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
- Therapeutic Response Evaluation and Adherence Trial (TREAT)
- Tagraxofusp (SL-401) in Patients With CMML or MF
- Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
- Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
- Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
- Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
- Haploidentical Hematopoietic Stem Cell Transplantation
- Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
- Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
- Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
- Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
- Selinexor (KPT-330) in Older Patients With Relapsed AML
- PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)
- Novel Dose Escalation to Predict Treatment With Hydroxyurea
- Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
- SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
- Losartan for Sickle Cell Kidney Disease
- Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease
- Novel Use Of Hydroxyurea in an African Region With Malaria
- Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
- Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
- Hydroxyurea in Pulmonary Arterial Hypertension
- Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
- Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
- Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
- Sickle Cell Disease - Stroke Prevention in Nigeria Trial
- Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
- Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
- Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
- Vascular Function Intervention Trial in Sickle Cell Disease
- Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
- Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)
- The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia
- A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
- A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
- Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
- Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
- Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
- Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation
- Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated
- Microvascular Blood Flow in Sickle Cell Anemia
- Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)
- A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
- Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
- Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
- A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
- Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
- Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
- Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
- A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
- Decitabine for High-Risk Sickle Cell Disease
- Treatment of Sickle Cell Anemia With Stem Cell Transplant
- Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
- Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
- Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
- Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Local
- Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients
- Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
- Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility
- Hydroxyurea in Primary Progressive Multiple Sclerosis
- Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients
- Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
- Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
- Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
- Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
- Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
- Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera
- Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer
- Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
- Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia
- Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia
- Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
- Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease
- Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
- Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
- Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
- Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
- Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
- Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
- Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
- A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients
- A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
- Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
- Reduced Intensity AlloSCT in(CML) With Persistent Disease
- Hydroxyurea in Young Children With Sickle Cell Anemia
- Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)
- Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
- A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
- A Trial of Hydroxyurea in Spinal Muscular Atrophy
- Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
- Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
- Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
- HSCT for High Risk Inherited Inborn Errors
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
- Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
- Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension
- Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
- Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
- A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
- Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
- Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
- Steroid Treatment for Sickle Cell Pain Crisis
- Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
- A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck
- A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
- PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED
- Primary Thrombocythaemia 1 Trial
- A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
- Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
- Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
- Stroke With Transfusions Changing to Hydroxyurea
- Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
- A Stratified Sickle Event Randomized Trial (ASSERT)
- Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
- Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
- VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
- Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
- Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
- A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
- Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate
- Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
- Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
- Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
- Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
- Radiation Therapy in Treating Patients With Glioblastoma
- Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
- Nitric Oxide to Improve Blood Flow in Sickle Cell Disease
- Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy
- Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
- Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
- Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection
- A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
- Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
- Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders
- Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
- Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer
- Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
- Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
- Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
- Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
- Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
- S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
- Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
- Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
- Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
- Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
- Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer
- Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults
- The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- A Study of MKC-442 in Combination With Other Anti-HIV Drugs
- A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients
- A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection
- A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
- Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
- Combination Drug Treatment of Pediatric HIV Infection
- Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
- A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses
- The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
- A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
- A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
- A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
- Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
- Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
- Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
Clinical trials list
click for details